Search
Rocket Pharmaceuticals Inc
RCKTAdd to Watchlist
3.250USD
+0.010+0.31%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
352.04MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-26The current earnings forecast score of Rocket Pharmaceuticals Inc is 6.86, ranking 320 out of 387 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 16.00 and a low of 2.00.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
9.386
Target Price
+189.70%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Rocket Pharmaceuticals Inc
RCKT
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Rocket Pharmaceuticals Inc's price target?
Analysts forecast that Rocket Pharmaceuticals Inc's price target is USD 8.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 2.00.
How have Rocket Pharmaceuticals IncRCKT's recent earnings per share performed?
The market expectation was USD -0.42, while Rocket Pharmaceuticals IncRCKT's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD 0.18.
What is the analyst rating for Rocket Pharmaceuticals Inc?
Based on the ratings of Rocket Pharmaceuticals Inc's stock from 14 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
